http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016515641-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
| filingDate | 2014-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016515641-A |
| titleOfInvention | Pharmaceutical composition comprising budesonide and formoterol |
| abstract | The present invention relates to a pharmaceutical formulation in the form of a dry powder applied by inhalation administration to the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an amount of budesonide greater than 5% w / w of the first powder or one of its pharmaceutically acceptable salts, an amount ranging from 5 to 70% w / w of the first powder. 1% powder of lactose and lactose in an amount ranging from 20-90% w / w of the first powder, formoterol in an amount greater than 1% w / w of the second powder or pharmaceutically acceptable thereof A second powder comprising one of the salts made, leucine in an amount ranging from 5 to 70% w / w of the second powder and lactose in an amount ranging from 20 to 90% w / w of the second powder And a third powder consisting of leucine in an amount ranging from 5 to 70% w / w of the third powder and lactose in an amount ranging from 20 to 90% w / w of the third powder. It relates to a pharmaceutical composition. The composition has a fine particle fraction (FPF) greater than 60% and an emitted fraction (DF) greater than 90%. [Selection figure] None |
| priorityDate | 2013-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.